{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:30:50Z","timestamp":1791261050803,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.schres.2016.04.036","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T02:17:37Z","timestamp":1462328257000},"page":"120-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study"],"prefix":"10.1016","volume":"174","author":[{"given":"Ashok","family":"Malla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldanie","family":"Rho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherezad","family":"Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridha","family":"Joober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2016.04.036_bb0005","series-title":"Scale for the Assessment of Negative Symptoms (SANS) Iowa City: University of Iowa","author":"Andreasen","year":"1983"},{"key":"10.1016\/j.schres.2016.04.036_bb0010","series-title":"Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen","year":"1984"},{"issue":"5","key":"10.1016\/j.schres.2016.04.036_bb0015","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2016.04.036_bb0020","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0447.1994.tb01604.x","article-title":"Axis V\u2014global assessment of functioning scale","volume":"90","author":"Bodlund","year":"1994","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2016.04.036_bb0025","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/JCP.0b013e3181ca03df","article-title":"A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis","volume":"30","author":"Cassidy","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2016.04.036_bb0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the extrapyramidal symptom rating scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.schres.2016.04.036_bb0035","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1185\/03007995.2014.908280","article-title":"A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults","volume":"30","author":"Citrome","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.schres.2016.04.036_bb0040","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00213-013-3241-3","article-title":"Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1year","volume":"231","author":"Crespo-Facorro","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2016.04.036_bb0045","series-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders","author":"First","year":"2005"},{"issue":"9","key":"10.1016\/j.schres.2016.04.036_bb0050","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1176\/ajp.149.9.1148","article-title":"Revising axis V for DSM-IV: a review of measures of social functioning","volume":"149","author":"Goldman","year":"1992","journal-title":"A. J. Psychiatry"},{"issue":"15","key":"10.1016\/j.schres.2016.04.036_bb0055","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder","volume":"64","author":"Harrison","year":"2004","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.schres.2016.04.036_bb0060","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00023210-200620120-00006","article-title":"Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder","volume":"20","author":"Harrison","year":"2006","journal-title":"CNS drugs"},{"issue":"1","key":"10.1016\/j.schres.2016.04.036_bb0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1751-7893.2012.00379.x","article-title":"Effectiveness of aripiprazole in adolescents and young adults with schizophrenia spectrum disorders: comparison of first-episode to recurrent psychosis","volume":"7","author":"Huang","year":"2013","journal-title":"Early Intervention in Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2016.04.036_bb0070","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/NMD.0000000000000288","article-title":"Early intervention for psychosis: A Canadian perspective","volume":"203","author":"Iyer","year":"2015","journal-title":"J. Nerv. Ment. Dis."},{"issue":"1","key":"10.1016\/j.schres.2016.04.036_bb0075","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1751-7893.2010.00163.x","article-title":"Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study","volume":"4","author":"Josiassen","year":"2010","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1016\/j.schres.2016.04.036_bb0080","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia (review)","volume":"1","author":"Khanna","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.schres.2016.04.036_bb0085","first-page":"38","article-title":"Trial of aripiprazole in the treatment of first-episode schizophrenia. Psychiatry Clin","volume":"64","author":"Lee","year":"2010","journal-title":"Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2016.04.036_bb0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/070674371205700204","article-title":"Medication-adherent first-episode psychosis patients also relapse: why?","volume":"57","author":"Levy","year":"2012","journal-title":"Can. J. Psychiatr."},{"issue":"2","key":"10.1016\/j.schres.2016.04.036_bb0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0920-9964(93)90049-O","article-title":"Three syndrome concept of schizophrenia: a factor analytic study","volume":"10","author":"Malla","year":"1993","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2016.04.036_bb0100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1440-1614.2003.01194.x","article-title":"A Canadian programme for early intervention in non-affective psychotic disorders","volume":"37","author":"Malla","year":"2003","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"05","key":"10.1016\/j.schres.2016.04.036_bb0105","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1017\/S0033291706007379","article-title":"Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study","volume":"36","author":"Malla","year":"2006","journal-title":"Psychol. Med."},{"issue":"11","key":"10.1016\/j.schres.2016.04.036_bb0110","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1017\/S0033291707002656","article-title":"Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service","volume":"38","author":"Malla","year":"2008","journal-title":"Psychol. Med."},{"issue":"02","key":"10.1016\/j.schres.2016.04.036_bb0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1017\/S0033291703001119","article-title":"Understanding delay in treatment for first-episode psychosis","volume":"34","author":"Norman","year":"2004","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.schres.2016.04.036_bb0120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/mds.23402","article-title":"Tardive dyskinesia and other movement disorders secondary to aripiprazole","volume":"26","author":"Pe\u00f1a","year":"2011","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.schres.2016.04.036_bb0125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2014.07.045","article-title":"Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12weeks of treatment in first treated episode of psychosis","volume":"159","author":"P\u00e9rez-Iglesias","year":"2014","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2016.04.036_bb0130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.jcp.0000130558.86125.5b","article-title":"A comparison of risperidone-induced weight gain across the age span","volume":"24","author":"Safer","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2016.04.036_bb0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40263-012-0026-x","article-title":"Lurasidone: in the treatment of schizophrenia","volume":"27","author":"Sanford","year":"2013","journal-title":"CNS drugs"},{"issue":"1","key":"10.1016\/j.schres.2016.04.036_bb0140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.schres.2015.07.003","article-title":"Sedentary behaviour is associated with elevated C-reactive protein levels in people with psychosis","volume":"168","author":"Stubbs","year":"2015","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2016.04.036_bb0145","first-page":"227","article-title":"Manual for the expanded brief psychiatric rating scale","volume":"3","author":"Ventura","year":"1993","journal-title":"Int. J. Method Psych."},{"issue":"4","key":"10.1016\/j.schres.2016.04.036_bb0150","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881114562090","article-title":"\u201cFirst do no harm.\u201d A systematic review of the prevalence and management of antipsychotic adverse effects","volume":"29","author":"Young","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2016.04.036_bb0155","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hup.2270","article-title":"Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52weeks follow-up in China","volume":"27","author":"Zhang","year":"2012","journal-title":"Hum. Psychopharmacol. Clin. Exp."}],"updated-by":[{"DOI":"10.1016\/j.schres.2018.03.009","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000}}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416301852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416301852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T09:51:58Z","timestamp":1536745918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996416301852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":31,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0920996416301852"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2016.04.036","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.schres.2018.03.009","asserted-by":"object"}]},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2016.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}